Oppenheimer & CO Inc Myriad Genetics Inc Transaction History
Oppenheimer & CO Inc
- $6.42 Billion
- Q3 2024
A detailed history of Oppenheimer & CO Inc transactions in Myriad Genetics Inc stock. As of the latest transaction made, Oppenheimer & CO Inc holds 18,066 shares of MYGN stock, worth $241,361. This represents 0.01% of its overall portfolio holdings.
Number of Shares
18,066
Previous 18,066
-0.0%
Holding current value
$241,361
Previous $441,000
12.02%
% of portfolio
0.01%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding MYGN
# of Institutions
253Shares Held
90.5MCall Options Held
100KPut Options Held
34K-
Black Rock Inc. New York, NY15.2MShares$202 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.3MShares$138 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.72MShares$89.7 Million0.03% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny5.18MShares$69.2 Million0.07% of portfolio
-
State Street Corp Boston, MA4.7MShares$62.8 Million0.01% of portfolio
About MYRIAD GENETICS INC
- Ticker MYGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 80,634,800
- Market Cap $1.08B
- Description
- Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...